PT3030255T - Nova imunoterapia contra diversos tumores, como o cancro do pulmão, incluindo cpcnp - Google Patents

Nova imunoterapia contra diversos tumores, como o cancro do pulmão, incluindo cpcnp

Info

Publication number: PT3030255T
Authority: PT; Portugal
Prior art keywords: lung cancer; against several; immunotherapy against; several tumors; including nsclc
Prior art date: 2013-08-05

Application number

PT147501753T

Other languages

English (en)

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-05

Filing date

2014-08-04

Publication date

2020-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52460698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3030255(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-08-05 Priority claimed from GBGB1313987.8A external-priority patent/GB201313987D0/en

2014-02-25 Priority claimed from GBGB1403297.3A external-priority patent/GB201403297D0/en

2014-08-04 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2020-01-15 Publication of PT3030255T publication Critical patent/PT3030255T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biophysics (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Mycology (AREA)
Oncology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Marine Sciences & Fisheries (AREA)
Toxicology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Peptides Or Proteins (AREA)

PT147501753T 2013-08-05 2014-08-04 Nova imunoterapia contra diversos tumores, como o cancro do pulmão, incluindo cpcnp PT3030255T (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361862213P	2013-08-05	2013-08-05
GBGB1313987.8A GB201313987D0 (en)	2013-08-05	2013-08-05	Novel immunotherapy against several tumors, such as lung cancer including NSCLC
GBGB1403297.3A GB201403297D0 (en)	2014-02-25	2014-02-25	Novel immunotherapy against several tumors, such as lung cancer, including NSCLC

Publications (1)

Publication Number	Publication Date
PT3030255T true PT3030255T (pt)	2020-01-15

Family

ID=52460698

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT147501753T PT3030255T (pt)	2013-08-05	2014-08-04	Nova imunoterapia contra diversos tumores, como o cancro do pulmão, incluindo cpcnp

Country Status (28)

Country	Link
US (3)	US20160168200A1 (pt)
EP (10)	EP3456339B1 (pt)
JP (1)	JP2016527293A (pt)
KR (9)	KR102098329B1 (pt)
CN (1)	CN105377290B (pt)
AU (10)	AU2014304544B2 (pt)
BR (1)	BR112016000810A2 (pt)
CA (4)	CA3073394A1 (pt)
CL (1)	CL2016000227A1 (pt)
CR (4)	CR20200139A (pt)
DK (2)	DK3030255T3 (pt)
EA (1)	EA035362B1 (pt)
ES (1)	ES2764406T3 (pt)
HU (1)	HUE047079T2 (pt)
IL (1)	IL243788B (pt)
LT (1)	LT3030255T (pt)
MX (1)	MX389568B (pt)
NZ (2)	NZ733168A (pt)
PE (3)	PE20181538A1 (pt)
PH (1)	PH12015502638A1 (pt)
PL (1)	PL3030255T3 (pt)
PT (1)	PT3030255T (pt)
RS (1)	RS59861B1 (pt)
SG (4)	SG10201802399WA (pt)
SI (1)	SI3030255T1 (pt)
TW (10)	TWI775117B (pt)
UA (1)	UA122661C2 (pt)
WO (1)	WO2015018805A1 (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10704021B2 (en)	2012-03-15	2020-07-07	Flodesign Sonics, Inc.	Acoustic perfusion devices
KR102383710B1 (ko) *	2013-08-05	2022-04-08	이매틱스 바이오테크놀로지스 게엠베하	Nsclc를 포함하는 폐암과 같은 여러 가지 종양에 대한 면역요법
CA2935960C (en)	2014-01-08	2023-01-10	Bart Lipkens	Acoustophoresis device with dual acoustophoretic chamber
MY199500A (en)	2015-03-17	2023-11-01	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201504502D0 (en) *	2015-03-17	2015-04-29	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
PH12021550850A1 (en)	2015-03-27	2022-10-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against various tumors
GB201505305D0 (en) *	2015-03-27	2015-05-13	Immatics Biotechnologies Gmbh	Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en)	2015-03-31	2015-05-13	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
TWI772927B (zh) *	2015-03-31	2022-08-01	德商英麥提克生物技術股份有限公司	用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架
GB201507030D0 (en)	2015-04-24	2015-06-10	Immatics Biotechnologies Gmbh	Immunotherapy against lung cancers, in particular NSCLC
US11377651B2 (en)	2016-10-19	2022-07-05	Flodesign Sonics, Inc.	Cell therapy processes utilizing acoustophoresis
US11708572B2 (en)	2015-04-29	2023-07-25	Flodesign Sonics, Inc.	Acoustic cell separation techniques and processes
KR20240161207A (ko)	2015-05-06	2024-11-12	이매틱스 바이오테크놀로지스 게엠베하	결장직장 암종(crc) 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드와 이의 골격의 조합
GB201507719D0 (en)	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CR20230191A (es) *	2015-05-20	2023-07-06	Dana Farber Cancer Inst Inc	NEOANTIGENOS COMPARTIDOS (Div. exp 2017-584)
IL292697A (en) *	2015-06-19	2022-07-01	Immatics Biotechnologies Gmbh	New peptides and their combination for use in immunotherapy and methods for creating supports for use against pancreatic cancer and other types of cancer
GB201511546D0 (en)	2015-07-01	2015-08-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA42294B1 (fr)	2015-07-01	2020-11-30	Immatics Biotechnologies Gmbh	Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
IL313594A (en) *	2015-07-06	2024-08-01	Immatics Biotechnologies Gmbh	Innovative peptides and a combination of peptides for use in immunotherapy against esophageal cancer and other types of cancer
GB201512369D0 (en) *	2015-07-15	2015-08-19	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en)	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201515321D0 (en) *	2015-08-28	2015-10-14	Immatics Biotechnologies Gmbh	Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US10159726B2 (en)	2015-08-28	2018-12-25	Immatics Biotechnologies Gmbh	Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
IL292864A (en)	2015-08-28	2022-07-01	Immatics Biotechnologies Gmbh	New peptides and a combination of peptides and supports for use in immunotherapy in certain types of cancer
HK1258386A1 (zh)	2015-10-05	2019-11-08	Immatics Biotechnologies Gmbh	用於小细胞肺癌和其他癌症免疫治疗的肽和肽组合物
GB201517538D0 (en) *	2015-10-05	2015-11-18	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
KR20170049024A (ko) *	2015-10-28	2017-05-10	숙명여자대학교산학협력단	ANKs1a 단백질 발현 또는 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 및 이의 스크리닝 방법
GB201521746D0 (en)	2015-12-10	2016-01-27	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
US10383896B2 (en)	2015-12-11	2019-08-20	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against various cancers
HK1255541A1 (zh)	2015-12-11	2019-08-23	Immatics Biotechnologies Gmbh	用於多种癌症免疫治疗的新型肽和肽组合物
GB201521894D0 (en)	2015-12-11	2016-01-27	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against various cancers
CA3008641A1 (en)	2015-12-16	2017-06-22	Gritstone Oncology, Inc.	Neoantigen identification, manufacture, and use
SG10202111399YA (en)	2015-12-22	2021-11-29	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201522667D0 (en) *	2015-12-22	2016-02-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) *	2016-02-19	2016-04-06	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603987D0 (en)	2016-03-08	2016-04-20	Immatics Biotechnologies Gmbh	Uterine cancer treatments
GB201604458D0 (en) *	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against cancers
KR20220097524A (ko) *	2016-04-06	2022-07-07	이매틱스 바이오테크놀로지스 게엠베하	Aml 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
SG11201808629UA (en) *	2016-04-21	2018-11-29	Immatics Biotechnologies Gmbh	Immunotherapy against melanoma and other cancers
US11214789B2 (en)	2016-05-03	2022-01-04	Flodesign Sonics, Inc.	Concentration and washing of particles with acoustics
JP7075125B2 (ja)	2016-05-25	2022-05-25	イマティクスバイオテクノロジーズゲーエムベーハー	標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en)	2016-05-25	2016-07-06	Immatics Biotechnologies Gmbh	Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
US10868749B2 (en) *	2016-07-26	2020-12-15	Motorola Mobility Llc	Method and apparatus for discovering neighborhood awareness networking devices based on presence
UA127162C2 (uk) *	2016-08-17	2023-05-24	Імматікс Біотекнолоджіс Гмбх	Антигенрозпізнавальна структура, яка специфічно та/або селективно зв'язується з антигенним пептидом col6a3
TW202304970A (zh) *	2016-08-26	2023-02-01	德商英麥提克生物技術股份有限公司	用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
WO2018057858A1 (en)	2016-09-23	2018-03-29	Memorial Sloan Kettering Cancer Center	Determinants of cancer response to immunotherapy
WO2018058490A1 (zh) *	2016-09-30	2018-04-05	武汉华大吉诺因生物科技有限公司	Col14a1衍生的肿瘤抗原多肽及其应用
US11276479B2 (en) *	2016-12-01	2022-03-15	Nantomics, Llc	Tumor antigenicity processing and presentation
KR102379955B1 (ko)	2016-12-08	2022-03-29	이매틱스 바이오테크놀로지스 게엠베하	짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de)	2016-12-08	2018-06-14	Immatics Biotechnologies Gmbh	T-Zellrezeptoren mit verbesserter Bindung
WO2018170313A1 (en) *	2017-03-16	2018-09-20	Advaxis, Inc.	Methods and compositions for increasing efficacy of vaccines
AU2018253341B2 (en) *	2017-04-10	2022-01-13	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
JP7357292B2 (ja) *	2017-04-28	2023-10-06	チュンシャンメディカルユニバーシティ	癌治療用ペプチド
PE20191842A1 (es)	2017-05-08	2019-12-31	Gritstone Oncology Inc	Vectores de neoantigeno de alfavirus
CR20200059A (es) *	2017-07-07	2020-06-01	Immatics Biotechnologies Gmbh	Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres
WO2019007974A1 (en)	2017-07-07	2019-01-10	Immatics Biotechnologies Gmbh	NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
WO2019075112A1 (en)	2017-10-10	2019-04-18	Gritstone Oncology, Inc.	IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
GB201717578D0 (en) *	2017-10-26	2017-12-13	Univ College Cardiff Consultants Ltd	Novel T-cell receptor
KR102905054B1 (ko)	2017-11-22	2025-12-29	시애틀 프로젝트 코포레이션	신생항원에 대한 접합 에피토프 제시 감소
EP3725092A4 (en)	2017-12-14	2021-09-22	FloDesign Sonics, Inc.	DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER
DE102018107224A1 (de)	2018-02-21	2019-08-22	Immatics Biotechnologies Gmbh	Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) *	2018-05-16	2020-05-01	德商英麥提克生物技術股份有限公司	用於抗癌免疫治療的肽
CN112368386A (zh) *	2018-05-23	2021-02-12	磨石肿瘤生物技术公司	共有抗原
CN110627895B (zh) *	2018-06-25	2021-03-23	北京大学	肺癌特异性tcr及其分析技术和应用
US10925947B2 (en) *	2018-06-29	2021-02-23	Immatics Biotechnologies Gmbh	A*03 restricted peptides for use in immunotherapy against cancers and related methods
EP3946440A4 (en) *	2019-04-02	2023-04-19	The General Hospital Corporation	Methods to enhance t cell regeneration
TW202523847A (zh)	2019-05-30	2025-06-16	美商磨石生物公司	經修飾之腺病毒
WO2021016109A1 (en) *	2019-07-19	2021-01-28	The Regents Of The University Of California	T-cell receptors and methods of use thereof
CN111020024A (zh) *	2019-12-05	2020-04-17	复旦大学附属眼耳鼻喉科医院	Tlr9的应用
CN111808908A (zh) *	2020-06-18	2020-10-23	华中科技大学同济医学院附属协和医院	一种促脑胶质瘤耐药的gaMSCs亚群的检测方法
WO2022125339A2 (en) *	2020-12-07	2022-06-16	The Trustees Of Indiana University	Methods to sensitize cancer cells to immune attack using atractylenolide i
WO2022125504A1 (en) *	2020-12-07	2022-06-16	Iogenetics, Llc	Bystander protein vaccines
CN113881707B (zh) *	2021-10-25	2023-07-14	中国人民解放军军事科学院军事医学研究院	调控脐带间充质干细胞免疫抑制作用的产品、方法及用途
CN113969264B (zh) *	2021-11-29	2023-12-08	中南大学	Cog5基因敲除的人胚胎干细胞系、构建方法及应用
CN115125203B (zh) *	2022-07-08	2023-10-27	珠海贝索细胞科学技术有限公司	一种Th2细胞体外培养方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8212000B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en)	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
DK171727B1 (da)	1978-12-22	1997-04-14	Biogen Inc	Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en)	1980-02-22	1982-08-03	Scripps Clinic & Research Foundation	Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en)	1981-09-25	1987-07-07	Genentech, Inc.	Hybrid human leukocyte interferons
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US4582800A (en)	1982-07-12	1986-04-15	Hoffmann-La Roche Inc.	Novel vectors and method for controlling interferon expression
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4677063A (en)	1985-05-02	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4810648A (en)	1986-01-08	1989-03-07	Rhone Poulenc Agrochimie	Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en)	1986-06-27	1990-01-30	The Administrators Of The Tulane Educational Fund	Method for synthesizing a peptide containing a non-peptide bond
ATE183513T1 (de)	1993-06-03	1999-09-15	Therapeutic Antibodies Inc	Herstellung von antikörperfragmenten
AUPM322393A0 (en)	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
JP4767371B2 (ja)	1996-01-17	2011-09-07	インペリアル・イノベイションズ・リミテッド	細胞障害性ｔリンパ球（ｃｔｌ）を用いた免疫療法
US5849589A (en)	1996-03-11	1998-12-15	Duke University	Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20040191260A1 (en)	2003-03-26	2004-09-30	Technion Research & Development Foundation Ltd.	Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP2316950A1 (en)	2000-03-27	2011-05-04	Technion Research and Development Foundation, Ltd.	Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
AU2001275246B2 (en)	2000-06-05	2006-06-29	Altor Bioscience Corporation	T cell receptor fusions and conjugates and methods of use thereof
US7919467B2 (en) *	2000-12-04	2011-04-05	Immunotope, Inc.	Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1442295B1 (en) *	2001-08-13	2008-07-30	Dana-Farber Cancer Institute, Inc.	Periostin-based diagnostic assays
US6992176B2 (en)	2002-02-13	2006-01-31	Technion Research & Development Foundation Ltd.	Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en)	2002-02-20	2003-08-28	Dyax Corp.	Mhc-peptide complex binding ligands
WO2004018633A2 (en) *	2002-08-20	2004-03-04	The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services	Abca13 nucleic acids and proteins, and uses thereof
AU2003271904B2 (en)	2002-10-09	2009-03-05	Adaptimmune Limited	Single chain recombinant T cell receptors
PT1558643E (pt)	2002-11-09	2009-08-24	Immunocore Ltd	Apresentação de um receptor das células t
GB0304068D0 (en)	2003-02-22	2003-03-26	Avidex Ltd	Substances
KR100535326B1 (ko) *	2004-01-20	2005-12-09	한국생명공학연구원	줄기 세포로부터 자연살해 세포로의 분화 조절용 유전자를유효성분으로 포함하는 분화 조절제
CN102875681A (zh)	2005-07-08	2013-01-16	拜奥根Idec马萨诸塞公司	抗-αvβ6抗体及其用途
SI1760089T1 (sl) *	2005-09-05	2009-12-31	Immatics Biotechnologies Gmbh	S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
ES2341295T3 (es) *	2005-09-05	2010-06-17	Immatics Biotechnologies Gmbh	Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
WO2007096142A2 (en) *	2006-02-22	2007-08-30	Philogen Spa	Vascular tumor markers
US20080107668A1 (en) *	2006-08-30	2008-05-08	Immunotope, Inc.	Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
SI2567707T1 (sl) *	2007-07-27	2017-01-31	Immatics Biotechnologies Gmbh	Sestava s tumorjem povezanih peptidov in zadevnih cepiv proti raku
WO2009036246A2 (en) *	2007-09-14	2009-03-19	Immunotope, Inc.	Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
CA2705292C (en)	2007-11-13	2016-06-21	Teva Biopharmaceuticals Usa, Inc.	Humanized antibodies against tl1a
US7996174B2 (en) *	2007-12-18	2011-08-09	Teradyne, Inc.	Disk drive testing
EP2262530A4 (en) *	2008-03-03	2012-12-05	Dyax Corp	Metalloproteinase-12 TIE PROTEINS
AU2009234444A1 (en) *	2008-04-11	2009-10-15	China Synthetic Rubber Corporation	Methods, agents and kits for the detection of cancer
DK2113253T3 (da)	2008-04-30	2010-07-19	Immatics Biotechnologies Gmbh	Ny sammensætning af tumorassocierede peptider, der bindes til humant leukocyt-antigen (HLA) klasse I eller II molekyler, til vaccinebrug
TWI526219B (zh) *	2008-06-19	2016-03-21	腫瘤療法科學股份有限公司	Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
BRPI0918768B1 (pt) *	2008-08-29	2022-08-30	Symphogen A/S	Composições de anticorpo recombinante de antireceptor do fator de crescimento epidérmico
RS53782B1 (sr) *	2008-10-01	2015-06-30	Immatics Biotechnologies Gmbh	Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
WO2010045388A2 (en) *	2008-10-14	2010-04-22	Dyax Corp.	Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
EP2221063A1 (en) *	2009-02-20	2010-08-25	Ganymed Pharmaceuticals AG	Methods and compositions for diagnosis and treatment of cancer
CA2762082C (en) *	2009-05-15	2018-06-19	Pacific Edge Biotechnology Limited	Markers for detection of gastric cancer
US20110033516A1 (en) *	2009-08-06	2011-02-10	Medical University Of South Carolina	Methods and compositions for bone healing by periostin
US8281198B2 (en)	2009-08-07	2012-10-02	Via Technologies, Inc.	User-initiatable method for detecting re-grown fuses within a microprocessor
US20120270769A1 (en)	2009-10-23	2012-10-25	Marsault Eric	Methods of using macrocyclic inhibitors of serine protease enzymes
TWI485245B (zh) *	2010-01-25	2015-05-21	Oncotherapy Science Inc	經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
KR101378919B1 (ko) *	2010-01-28	2014-04-14	포항공과대학교 산학협력단	혈액으로부터 직접 폐암 진단 및 폐암의 서브타입 진단이 가능한 마커를 선별하는 시스템 생물학적 방법 및 이로부터 선별된 혈액으로부터 직접 폐암 진단 및 폐암 서브타입 진단이 가능한 마커
GB201004575D0 (en) *	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) *	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en)	2010-04-16	2010-06-02	Immatics Biotechnologies Gmbh	Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) *	2010-06-02	2010-07-21	Immatics Biotechnologies Gmbh	Improved cancer therapy based on tumour associated antigens derived from cyclin D1
WO2012056407A1 (en)	2010-10-26	2012-05-03	Technion Research & Development Foundation Ltd.	Antibodies which bind soluble t-cell receptor ligands
US9028810B2 (en) *	2010-12-20	2015-05-12	Ajou University Industry—Academic Cooperations Foundatin	Composition for inducing migration of neural stem cells containing periostin as effective ingredient
WO2013057586A1 (en)	2011-10-19	2013-04-25	Oslo Universitetssykehus Hf	Compositions and methods for producing soluble t - cell receptors
GB201319446D0 (en) *	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors

2014
- 2014-08-01 TW TW109124796A patent/TWI775117B/zh not_active IP Right Cessation
- 2014-08-01 TW TW109124802A patent/TWI777198B/zh not_active IP Right Cessation
- 2014-08-01 TW TW109124803A patent/TWI819228B/zh not_active IP Right Cessation
- 2014-08-01 TW TW109124798A patent/TWI776192B/zh not_active IP Right Cessation
- 2014-08-01 TW TW107123070A patent/TWI714869B/zh not_active IP Right Cessation
- 2014-08-01 TW TW109124795A patent/TWI777194B/zh not_active IP Right Cessation
- 2014-08-01 TW TW103126327A patent/TWI636065B/zh not_active IP Right Cessation
- 2014-08-01 TW TW109124797A patent/TWI777195B/zh not_active IP Right Cessation
- 2014-08-01 TW TW109124801A patent/TWI777197B/zh not_active IP Right Cessation
- 2014-08-01 TW TW109124799A patent/TWI777196B/zh not_active IP Right Cessation
- 2014-08-04 EP EP18201334.2A patent/EP3456339B1/en active Active
- 2014-08-04 KR KR1020167000976A patent/KR102098329B1/ko not_active Expired - Fee Related
- 2014-08-04 UA UAA201600268A patent/UA122661C2/uk unknown
- 2014-08-04 NZ NZ733168A patent/NZ733168A/en not_active IP Right Cessation
- 2014-08-04 JP JP2016532350A patent/JP2016527293A/ja active Pending
- 2014-08-04 CR CR20200139A patent/CR20200139A/es unknown
- 2014-08-04 KR KR1020217001136A patent/KR102317816B1/ko active Active
- 2014-08-04 PE PE2018001559A patent/PE20181538A1/es unknown
- 2014-08-04 KR KR1020207029977A patent/KR102213552B1/ko not_active Expired - Fee Related
- 2014-08-04 SG SG10201802399WA patent/SG10201802399WA/en unknown
- 2014-08-04 EA EA201690016A patent/EA035362B1/ru unknown
- 2014-08-04 SG SG10202002608WA patent/SG10202002608WA/en unknown
- 2014-08-04 EP EP19202037.8A patent/EP3616709B1/en active Active
- 2014-08-04 CA CA3073394A patent/CA3073394A1/en active Pending
- 2014-08-04 LT LTEP14750175.3T patent/LT3030255T/lt unknown
- 2014-08-04 HU HUE14750175A patent/HUE047079T2/hu unknown
- 2014-08-04 EP EP14750175.3A patent/EP3030255B1/en active Active
- 2014-08-04 EP EP19202000.6A patent/EP3613427B1/en active Active
- 2014-08-04 ES ES14750175T patent/ES2764406T3/es active Active
- 2014-08-04 CN CN201480035925.8A patent/CN105377290B/zh not_active Expired - Fee Related
- 2014-08-04 EP EP19202064.2A patent/EP3616712A1/en not_active Withdrawn
- 2014-08-04 EP EP19202056.8A patent/EP3616711B1/en active Active
- 2014-08-04 PE PE2020000409A patent/PE20201284A1/es unknown
- 2014-08-04 CR CR20210464A patent/CR20210464A/es unknown
- 2014-08-04 EP EP19202046.9A patent/EP3616710B1/en active Active
- 2014-08-04 AU AU2014304544A patent/AU2014304544B2/en not_active Ceased
- 2014-08-04 CA CA3073256A patent/CA3073256A1/en active Pending
- 2014-08-04 EP EP19202010.5A patent/EP3616707A1/en not_active Withdrawn
- 2014-08-04 KR KR1020187026992A patent/KR102217680B1/ko not_active Expired - Fee Related
- 2014-08-04 CR CR20180508A patent/CR20180508A/es unknown
- 2014-08-04 CA CA2912500A patent/CA2912500C/en active Active
- 2014-08-04 BR BR112016000810A patent/BR112016000810A2/pt not_active IP Right Cessation
- 2014-08-04 WO PCT/EP2014/066755 patent/WO2015018805A1/en not_active Ceased
- 2014-08-04 CA CA3020939A patent/CA3020939C/en active Active
- 2014-08-04 SG SG10202002612PA patent/SG10202002612PA/en unknown
- 2014-08-04 KR KR1020207029963A patent/KR102213554B1/ko not_active Expired - Fee Related
- 2014-08-04 KR KR1020187026995A patent/KR102098327B1/ko not_active Expired - Fee Related
- 2014-08-04 PE PE2015002616A patent/PE20160717A1/es active Application Revival
- 2014-08-04 SI SI201431453T patent/SI3030255T1/sl unknown
- 2014-08-04 KR KR1020207029978A patent/KR102213551B1/ko not_active Expired - Fee Related
- 2014-08-04 DK DK14750175.3T patent/DK3030255T3/da active
- 2014-08-04 US US14/908,078 patent/US20160168200A1/en not_active Abandoned
- 2014-08-04 MX MX2016001426A patent/MX389568B/es unknown
- 2014-08-04 PL PL14750175T patent/PL3030255T3/pl unknown
- 2014-08-04 SG SG11201510580UA patent/SG11201510580UA/en unknown
- 2014-08-04 KR KR1020207029965A patent/KR102213556B1/ko not_active Expired - Fee Related
- 2014-08-04 EP EP19202028.7A patent/EP3616708B1/en active Active
- 2014-08-04 KR KR1020207018007A patent/KR102211542B1/ko not_active Expired - Fee Related
- 2014-08-04 NZ NZ714163A patent/NZ714163A/en not_active IP Right Cessation
- 2014-08-04 PT PT147501753T patent/PT3030255T/pt unknown
- 2014-08-04 DK DK18201334.2T patent/DK3456339T3/da active
- 2014-08-04 RS RS20191676A patent/RS59861B1/sr unknown
- 2014-08-04 EP EP19171543.2A patent/EP3578196A1/en not_active Withdrawn
2015
- 2015-11-26 PH PH12015502638A patent/PH12015502638A1/en unknown
2016
- 2016-01-08 CR CR20160018A patent/CR20160018A/es unknown
- 2016-01-26 IL IL24378816A patent/IL243788B/en active IP Right Grant
- 2016-01-28 CL CL2016000227A patent/CL2016000227A1/es unknown
- 2016-11-21 US US15/357,838 patent/US10071148B2/en active Active
2017
- 2017-06-30 US US15/639,058 patent/US9943579B2/en active Active
2018
- 2018-01-17 AU AU2018200389A patent/AU2018200389B2/en not_active Ceased
2020
- 2020-08-17 AU AU2020220038A patent/AU2020220038B2/en not_active Ceased
- 2020-08-17 AU AU2020220041A patent/AU2020220041B2/en not_active Ceased
- 2020-08-17 AU AU2020220039A patent/AU2020220039B2/en not_active Ceased
- 2020-08-17 AU AU2020220040A patent/AU2020220040B2/en not_active Ceased
- 2020-08-17 AU AU2020220045A patent/AU2020220045B2/en not_active Ceased
- 2020-08-17 AU AU2020220043A patent/AU2020220043B2/en not_active Ceased
- 2020-08-17 AU AU2020220044A patent/AU2020220044B2/en not_active Ceased
- 2020-08-17 AU AU2020220042A patent/AU2020220042B2/en not_active Ceased

Also Published As

Publication number	Publication date
EP3616709B1 (en)	2025-01-15
US20160168200A1 (en)	2016-06-16
CA3073256A1 (en)	2015-02-12
AU2014304544A1 (en)	2015-12-03
KR102213552B1 (ko)	2021-02-05
HK1222121A1 (zh)	2017-06-23
KR20200122417A (ko)	2020-10-27
AU2020220040B2 (en)	2021-11-25
CR20160018A (es)	2016-06-08
CR20180508A (es)	2019-02-27
PE20201284A1 (es)	2020-11-24
RS59861B1 (sr)	2020-03-31
KR102213554B1 (ko)	2021-02-05
TWI775117B (zh)	2022-08-21
DK3030255T3 (da)	2020-01-20
TWI819228B (zh)	2023-10-21
TW202041519A (zh)	2020-11-16
UA122661C2 (uk)	2020-12-28
EP3616710B1 (en)	2025-01-15
EP3616707A1 (en)	2020-03-04
CA2912500A1 (en)	2015-02-12
US9943579B2 (en)	2018-04-17
AU2020220038B2 (en)	2021-11-25
TW202041518A (zh)	2020-11-16
KR102217680B1 (ko)	2021-02-18
AU2020220039A1 (en)	2020-09-03
EP3613427A1 (en)	2020-02-26
SG10202002608WA (en)	2020-04-29
CA3020939A1 (en)	2015-02-12
AU2020220042A1 (en)	2020-09-03
KR102213551B1 (ko)	2021-02-05
AU2020220041A1 (en)	2020-09-03
EP3616711A1 (en)	2020-03-04
KR20200078681A (ko)	2020-07-01
PH12015502638A1 (en)	2016-03-07
KR102213556B1 (ko)	2021-02-05
TWI777196B (zh)	2022-09-11
AU2020220045A1 (en)	2020-09-03
AU2020220040A1 (en)	2020-09-03
CR20200139A (es)	2020-09-02
TWI636065B (zh)	2018-09-21
HUE047079T2 (hu)	2020-04-28
TWI777195B (zh)	2022-09-11
MX389568B (es)	2025-03-20
EP3616710A1 (en)	2020-03-04
EP3616709A1 (en)	2020-03-04
AU2020220045B2 (en)	2021-11-25
BR112016000810A2 (pt)	2017-12-12
EP3616712A1 (en)	2020-03-04
EP3578196A1 (en)	2019-12-11
EP3616708B1 (en)	2025-01-08
US20170202937A1 (en)	2017-07-20
TWI777198B (zh)	2022-09-11
SG10201802399WA (en)	2018-04-27
LT3030255T (lt)	2020-01-27
AU2020220041B2 (en)	2021-11-25
AU2020220042B2 (en)	2021-11-25
NZ714163A (en)	2017-07-28
PE20181538A1 (es)	2018-09-26
TWI777197B (zh)	2022-09-11
SG11201510580UA (en)	2016-02-26
CR20210464A (es)	2021-10-26
AU2020220044A1 (en)	2020-09-03
KR102098329B1 (ko)	2020-04-09
TW202041515A (zh)	2020-11-16
EP3030255B1 (en)	2019-10-09
IL243788A0 (en)	2016-04-21
KR20180105754A (ko)	2018-09-28
AU2020220038A1 (en)	2020-09-03
NZ733168A (en)	2020-04-24
PL3030255T3 (pl)	2020-05-18
ES2764406T3 (es)	2020-06-03
KR102317816B1 (ko)	2021-10-26
CA3020939C (en)	2023-01-03
KR20180107295A (ko)	2018-10-01
TW202041522A (zh)	2020-11-16
EP3616708A1 (en)	2020-03-04
KR20200122418A (ko)	2020-10-27
EP3456339B1 (en)	2021-10-20
DK3456339T3 (da)	2021-12-06
TW202041520A (zh)	2020-11-16
EP3030255A1 (en)	2016-06-15
TW202041517A (zh)	2020-11-16
EA201690016A1 (ru)	2016-05-31
KR102211542B1 (ko)	2021-02-02
CN105377290A (zh)	2016-03-02
TWI777194B (zh)	2022-09-11
IL243788B (en)	2019-10-31
KR102098327B1 (ko)	2020-04-08
US20170319675A1 (en)	2017-11-09
CA3073394A1 (en)	2015-02-12
MX2016001426A (es)	2016-05-05
KR20200122419A (ko)	2020-10-27
EP3456339A3 (en)	2019-03-27
AU2018200389A1 (en)	2018-02-08
CN105377290B (zh)	2019-09-03
TWI776192B (zh)	2022-09-01
SG10202002612PA (en)	2020-05-28
CL2016000227A1 (es)	2016-08-05
WO2015018805A1 (en)	2015-02-12
TW201900669A (zh)	2019-01-01
TW201506043A (zh)	2015-02-16
AU2014304544B2 (en)	2017-10-26
CA2912500C (en)	2021-08-24
EP3616711B1 (en)	2025-01-15
AU2020220043B2 (en)	2021-11-25
AU2020220039B2 (en)	2021-05-20
TW202041521A (zh)	2020-11-16
SI3030255T1 (sl)	2020-02-28
KR20160038889A (ko)	2016-04-07
EP3613427B1 (en)	2025-01-15
US10071148B2 (en)	2018-09-11
PE20160717A1 (es)	2016-07-21
TW202041516A (zh)	2020-11-16
AU2020220044B2 (en)	2021-11-25
AU2018200389B2 (en)	2020-07-16
EA035362B1 (ru)	2020-06-02
KR20210008169A (ko)	2021-01-20
AU2020220043A1 (en)	2020-09-03
EP3456339A2 (en)	2019-03-20
JP2016527293A (ja)	2016-09-08
KR20200123266A (ko)	2020-10-28
TWI714869B (zh)	2021-01-01

Publication	Publication Date	Title
IL243788A0 (en)	2016-04-21	New immunotherapy against various tumors such as lung cancer which includes nsclc
IL295031B1 (en)	2023-04-01	Innovative immunotherapy against several tumors, such as lung cancer, including nsclc
GB201507030D0 (en)	2015-06-10	Immunotherapy against lung cancers, in particular NSCLC
EP2971284A4 (en)	2017-01-18	Subtyping lung cancers
EP2968254A4 (en)	2017-03-15	Methods of treating lung cancer
GB201322725D0 (en)	2014-02-05	Cancer therapy
EP3090264A4 (en)	2017-06-07	Circulating tumor cell diagnostics for lung cancer
SG11201509707QA (en)	2015-12-30	Cancer therapy
EP2994148B8 (en)	2017-08-30	Cancer therapy
EP3007756A4 (en)	2017-02-22	Catheter-assisted tumor treatment
EP3044593A4 (en)	2017-05-17	Cancer therapy
EP2961412A4 (en)	2016-11-09	CANCER THERAPY
IL271367A (en)	2020-01-30	Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
EP3015476A4 (en)	2017-05-24	Tumor biomarker
EP3277325A4 (en)	2018-12-05	Combination immunotherapy for small cell lung cancer
GB201313987D0 (en)	2013-09-18	Novel immunotherapy against several tumors, such as lung cancer including NSCLC
IL245477A0 (en)	2016-06-30	Diagnosis of lung cancer
GB201403297D0 (en)	2014-04-09	Novel immunotherapy against several tumors, such as lung cancer, including NSCLC
HK1224926A1 (en)	2017-09-01	Tumor antigens for determining cancer therapy
EP3077812A4 (en)	2017-06-07	Methods for the prognosis of breast cancer
GB201519261D0 (en)	2015-12-16	Novel Immunotherapeutic treatments for tumours
GB201317213D0 (en)	2013-11-13	Cancer Therapy